KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc. (KALV) is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule protease inhibitors for diseases with significant unmet needs. The company's research and development efforts are primarily directed towards therapies for hereditary angioedema (HAE) and other related indications. KalVista utilizes its expertise in protease inhibition to create innovative solutions aimed at improving the lives of patients affected by these conditions. By targeting specific proteases involved in disease pathways, KalVista seeks to develop oral and convenient treatment options. The company operates within the biotechnology and pharmaceutical sectors, contributing to advancements in precision medicine and targeted therapies.